Marc Feldmann
Chairman bij HEMOGENYX PHARMACEUTICALS PLC
Vermogen: 30 765 $ op 31-03-2024
Profiel
Dr. Marc Feldmann is a Co-Chairman at 180 Life Corp., an Executive Chairman at HemoGenyx Pharmaceuticals Plc, a Co-Chairman at CannBioRex Pharmaceuticals Corp., a Professor at University of Oxford, a Chairman at ReFormation Pharmaceuticals Corp., a Member at National Academy of Sciences and a Professor-Emeritus at Kennedy Institute of Rheumatology.
He is on the Board of Directors at Enosi Life Sciences Corp., Katexco Pharmaceuticals Corp., Lupus Research Alliance, Inc. and StormBio, Inc. Dr. Feldmann was previously employed as a Co-Executive Chairman by KBL Merger Corp.
IV, a Co-Founder by Nuon Therapeutics, Inc., and an Executive Co-Chairman by 180 Life Sciences Corp.
He received his doctorate degree from the University of Melbourne.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
180 LIFE SCIENCES CORP.
1.55% | 28-12-2023 | 13 204 ( 1.55% ) | 30 765 $ | 31-03-2024 |
| 31-12-2022 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Marc Feldmann
| Bedrijven | Functie | Begin |
|---|---|---|
| HEMOGENYX PHARMACEUTICALS PLC | Chairman | 09-04-2018 |
Kennedy Institute of Rheumatology
 Kennedy Institute of Rheumatology Pharmaceuticals: MajorHealth Technology Part of University of Oxford, Kennedy Institute of Rheumatology is a research facility that focuses on studying host-microbe crosstalk in health and disease, with a particular emphasis on inflammatory bowel disease, colorectal cancer, and inflammatory arthritis. The Kennedy Institute of Rheumatology is based in Headington, UK. The institute employs advanced microscopy methods and cutting-edge technology to generate a wide variety of data, which is made available to researchers through the Research Informatics team. The facility aims to future-proof excellence for Bioimaging within Oxford, keeping it competitive with international research. | Corporate Officer/Principal | - |
CannBioRex Pharmaceuticals Corp.
 CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Founder | 08-03-2018 |
ReFormation Pharmaceuticals Corp.
 ReFormation Pharmaceuticals Corp. Agricultural Commodities/MillingProcess Industries ReFormation Pharmaceuticals Corp. operates as a medical marijuana pharmaceutical company. It focuses on repairing vital organs by combining cannabinoids and an endogenous trigger of repair. The company was founded by Marc Feldmann and Jagdeep Nanchahal and is headquartered in Toronto, Canada. | Founder | - |
National Academy of Sciences
 National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Corporate Officer/Principal | - |
Katexco Pharmaceuticals Corp.
 Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada. | Founder | - |
StormBio, Inc.
 StormBio, Inc. Drugstore ChainsRetail Trade StormBio, Inc. provides biopharmaceutical services. It develops therapeutics for treating highly pathogenic influenza. The company is headquartered in Westfield, NJ. | Director/Board Member | - |
| University of Oxford | Corporate Officer/Principal | 01-01-2011 |
Lupus Research Alliance, Inc.
 Lupus Research Alliance, Inc. Miscellaneous Commercial ServicesCommercial Services Lupus Research Alliance, Inc. provides research and development for the treatment of lupus disease. The company is headquartered in New York, NY. | Director/Board Member | - |
| ░░░ ░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
Eerdere bekende functies van Marc Feldmann
| Bedrijven | Functie | Einde |
|---|---|---|
| ░░░ ░░░░ ░░░░░░░░ ░░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░ ░░░░░░░░ ░░░░░ | ░░░░░░░░ | - |
| ░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | - |
Opleiding van Marc Feldmann
| University of Melbourne | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| 180 LIFE SCIENCES CORP. | Health Technology |
| Bedrijven in privébezit | 12 |
|---|---|
StormBio, Inc.
StormBio, Inc. Drugstore ChainsRetail Trade StormBio, Inc. provides biopharmaceutical services. It develops therapeutics for treating highly pathogenic influenza. The company is headquartered in Westfield, NJ. | Retail Trade |
National Academy of Sciences
National Academy of Sciences Miscellaneous Commercial ServicesCommercial Services National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC. | Commercial Services |
Nuon Therapeutics, Inc.
 Nuon Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nuon Therapeutics Inc. develops therapies to treat inflammation and neurological diseases. The company focuses on the development and commercialization of new therapies for autoimmune disease and inflammation includes rheumatoid arthritis and multiple sclerosis. Nuon Therapeutics was founded by Kim Puloma Kamdar, Marc Feldmann, Lawrence J. Steinman and Michael Selley in 2006 and is headquartered in San Mateo, CA. | Health Technology |
Lupus Research Alliance, Inc.
Lupus Research Alliance, Inc. Miscellaneous Commercial ServicesCommercial Services Lupus Research Alliance, Inc. provides research and development for the treatment of lupus disease. The company is headquartered in New York, NY. | Commercial Services |
Kennedy Institute of Rheumatology
Kennedy Institute of Rheumatology Pharmaceuticals: MajorHealth Technology Part of University of Oxford, Kennedy Institute of Rheumatology is a research facility that focuses on studying host-microbe crosstalk in health and disease, with a particular emphasis on inflammatory bowel disease, colorectal cancer, and inflammatory arthritis. The Kennedy Institute of Rheumatology is based in Headington, UK. The institute employs advanced microscopy methods and cutting-edge technology to generate a wide variety of data, which is made available to researchers through the Research Informatics team. The facility aims to future-proof excellence for Bioimaging within Oxford, keeping it competitive with international research. | Health Technology |
KBL Merger Corp. IV
 KBL Merger Corp. IV Financial ConglomeratesFinance KBL Merger Corp. IV is a blank check company, which focuses on acquiring an operating company in the healthcare and related wellness industry. The company was founded on September 7, 2016 and is headquartered in New York, NY. | Finance |
| HemoGenyx Pharmaceuticals Plc | |
CannBioRex Pharmaceuticals Corp.
CannBioRex Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology CannBioRex Pharmaceuticals Corp. is a research company that specializes in the clinical development of synthetic pharmaceutical grade cannabinoid compounds for the treatment in rheumatoid arthritis and related arthritic diseases. It also plans to develop novel orally available and patentable medications to treat arthritis, multiple sclerosis, diabetes, psoriasis, obesity and fatty liver, and various painful conditions. The company was founded by Marc Feldmann and Raphael Mechoulam on March 8, 2018 and is headquartered in Toronto, Canada. | Health Technology |
ReFormation Pharmaceuticals Corp.
ReFormation Pharmaceuticals Corp. Agricultural Commodities/MillingProcess Industries ReFormation Pharmaceuticals Corp. operates as a medical marijuana pharmaceutical company. It focuses on repairing vital organs by combining cannabinoids and an endogenous trigger of repair. The company was founded by Marc Feldmann and Jagdeep Nanchahal and is headquartered in Toronto, Canada. | Process Industries |
Katexco Pharmaceuticals Corp.
Katexco Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Katexco Pharmaceuticals Corp. operates as medical marijuana company that engages in the development of orally available therapies harnessing endocannabinoid and nicotine receptors to treat inflammatory diseases. The company was founded by Jonathan Rothbard, Lawrence Steinman and Marc Feldmann and is headquartered in Toronto, Canada. | Health Technology |
180 Life Corp.
 180 Life Corp. Pharmaceuticals: MajorHealth Technology 180 Life Sciences Corp. engages in manufacture of pharmaceutical products. The company is headquartered in New York. | Health Technology |
Enosi Life Sciences Corp.
 Enosi Life Sciences Corp. BiotechnologyHealth Technology Enosi Life Sciences Corp. is a drug research and development company that focuses on providing therapeutics for autoimmune diseases and cancer. The private company is based in San Diego, CA, and was founded in 2018 by H. Michael Shepard and Marc Feldmann. Enosi Life Sciences combines their expertise with Dr. James N. Woody's medical, scientific, and management expertise to expand therapeutic options. The company was founded by Professor Sir Marc Feldmann and Dr. H. Michael Shepard, who are world-renowned scientists in the field of cancer and autoimmune diseases. Patrick W. Gray has been the CEO of the company since 2021. | Health Technology |
